[{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"BioLexis Pte. Ltd","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ BioLexis Pte. Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ BioLexis Pte. Ltd"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Syntone Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Private Placement","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.02,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Syntone Ventures LLC","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Syntone Ventures LLC"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"GMS Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Funding","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.040000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ GMS Ventures","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ GMS Ventures"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Public Offering","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.059999999999999998,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"AmerisourceBergen","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Bevacizumab","moa":"VEGF","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ AmerisourceBergen","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ AmerisourceBergen"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"VEGF A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Brookline Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ Brookline Capital","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Brookline Capital"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"M.S. Howells & Co.","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Outlook Therapeutics \/ M.S. Howells & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ M.S. Howells & Co."},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Great Point Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Outlook Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Great Point Partners","highestDevelopmentStatusID":"12","companyTruncated":"Outlook Therapeutics \/ Great Point Partners"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.16,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Syntone Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Syntone Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Syntone Ventures"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab Gamma","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Outlook Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Outlook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Bevacizumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Outlook Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Outlook Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Outlook Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Outlook Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
